Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

AbC-19 rapid antibody test performance evaluation

9 Jul 2021 09:08

RNS Number : 7496E
Omega Diagnostics Group PLC
09 July 2021
 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

 

AbC-19TM rapid antibody test performance evaluation

Peer-reviewed performance evaluation and self-test user experience of AbC 19TM

 

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes

the press release issued today by the UK Rapid Test Consortium ("UK-RTC"), of which Omega is a partner, welcoming the publication of two peer-reviewed studies conducted by Ulster University and involving AbC-19™, a lateral flow test for the detection of neutralising IgG antibodies to the full trimeric spike protein of the SARS-CoV-2 virus.

 

Highlights from the studies include:

· Excellent laboratory validation performance metrics for the AbC-19™ rapid test for SARS-CoV-2 spike protein IgG antibody detection and semi-quantitative correlation withlaboratory ELISA methods assaying IgG antibodies to the spike protein of the SARS-CoV-2 virus.

· AbC-19™ showed sensitivity of 97.58% and specificity of 99.59% when using evaluation methods as defined by the MHRA for Target Product Profile of an antibody test.

· In addition, the study notes that IgG antibodies to the SARS-CoV-2 virus were detected 10 months after infection. Understanding the longevity of COVID-19 antibodies is importantboth immunologically and in helping to guide pandemic exit protocols.

· Positive user experience score from 1,544 participants who used AbC-19™ as a 'self-test'

 

Professor Chris Molloy, Independent chairman of the UK Rapid Test Consortium said: "We are entering a phase of the pandemic where testing for immunity will become as or more important than testing for infection. Rapid, accurate immunity tests are therefore a critical tool for citizens and public health providers to embrace. 

 

"Development of multiple antibody tests, and semi-quantitative approaches will enhance this portfolio and enable the most rapid global recovery."

 

The UK-RTC press release can be read in full here: 

https://www.abc19.com/peer-reviewed-performance-evaluation-and-self-test-user-experience-of-abc-19/

 

 

Contacts: 

 

Omega Diagnostics Group PLC

www.omegadiagnostics.com

Colin King, Chief Executive

via Walbrook PR

Kieron Harbinson, Group Finance Director

finnCap Ltd

Tel: 020 7220 0500

Geoff Nash/Edward Whiley (Corporate Finance)

Alice Lane (ECM)

Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAEAPXNEEKFEEA
Date   Source Headline
16th Apr 200710:36 amRNSEuropean patent grant
4th Apr 20077:02 amRNSAppointment of Distributor
30th Mar 20076:20 pmRNSInterim Results
15th Dec 20062:28 pmRNSTotal Voting Rights
6th Nov 20067:00 amRNSEuropean patent grant
4th Oct 20069:37 amRNSIssue of Equity
27th Sep 20067:00 amRNSInterim Results
20th Sep 20065:15 pmRNSChange of Name
19th Sep 20067:02 amRNSCommencement of dealings
18th Sep 20062:58 pmRNSResult of EGM
5th Sep 200612:13 pmRNSSch1-Quintessentially English
24th Aug 200611:51 amRNSRestoration of Trading-Amend
24th Aug 200610:30 amRNSRestoration of Trading
24th Aug 200610:30 amRNSRestoration-Quintessentially
24th Aug 20067:00 amRNSAcquisition and Placing
8th May 200612:34 pmRNSResult of AGM
3rd Apr 20067:02 amRNSTemporary Suspension
3rd Apr 20067:01 amRNSSuspension - Quintessentially
23rd Mar 20064:13 pmRNSFinal Results
28th Sep 20057:02 amRNSInterim Results
12th Aug 200512:17 pmRNSResult of AGM
28th Jun 200511:40 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.